Sharekhan

Mankind Pharma Ltd

Mon 7/07/2025,11:14:59 | NSE : MANKIND

₹ 2428.70-10.80 (-0.44%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 2442.50

Previous Close

₹ 2439.50

Volume

159820

Mkt Cap ( Rs. Cr)

₹100239.43

High

₹ 2465.60

Low

₹ 2425.00

52 Week High

₹ 3054.80

52 Week Low

₹ 1901.05

Book Value Per Share

₹ 256.00

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Mankind Pharma Ltd

Your Vote -

Buy

43.38%

Hold

25.00%

Sell

31.62%

43.38%

136 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

34%

Sell Order Quantity

66%

Bid Price

Qty

2426.10

3

2426.00

40

2426.00

2

2426.00

19

2425.00

1

Bid Total

35134

Bid Price

Qty

2426.30

15

2426.00

21

2427.00

15

2427.00

28

2427.00

22

Bid Total

68438

Option Chain

Analyzes market sentiment, predicts Mankind Pharma Ltd' movement.

Call Price Open interest Strike Price Put Price Open interest

News

Media spotlight triggers stock stock attention, sentiment.

  • Mankind Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    4 Jul 2025, 3:46PM Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Mankind Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    4 Jul 2025, 3:42PM Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
  • Mankind Pharma - Copy of Newspaper Publication

    4 Jul 2025, 12:38PM Newspaper Advertisement for information regarding the 34th Annual General Meeting of Mankind Pharma Limited
  • Mankind Pharma - General Updates

    3 Jul 2025, 3:43PM Intimation of the date of 34th Annual General Meeting of the Company
  • Mankind Pharma - Intimation Of The Date Of 34Th Annual General Meeting (AGM) Of The Company

    3 Jul 2025, 3:41PM Intimation of the date of 34th AGM of the Company
  • Mankind Pharma - Trading Window-XBRL

    26 Jun 2025, 4:39PM MANKIND PHARMA LIMITED has informed the Exchange about Closure of Trading Window
  • Mankind Pharma - Trading Window

    26 Jun 2025, 4:31PM Mankind Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    16 Jun 2025, 12:59PM Intimation of participation in the Investor Conferences
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    16 Jun 2025, 12:54PM Intimation of participation in the Investor Conferences
  • Mankind Pharma - Alteration Of Capital and Fund Raising-XBRL

    10 Jun 2025, 11:06AM MANKIND PHARMA LIMITED has informed the Exchange regarding Allotment of Securities
  • Mankind Pharma - ESOP/ESOS/ESPS

    10 Jun 2025, 10:54AM Allotment of 57,709 Equity Shares under Mankind Employee Stock Option Plan 2022.
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    10 Jun 2025, 10:47AM Allotment of 57,709 Equity Shares under Mankind Employee Stock Option Plan 2022
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Acquisition

    2 Jun 2025, 7:01PM Intimation of incorporation of KINDCARE FOUNDATION, a Wholly Owned Subsidiary Company
  • Mankind Pharma - Incorporation-XBRL

    2 Jun 2025, 6:57PM Mankind Pharma Limited has informed the Exchange regarding Incorporation
  • Mankind Pharma - Incorporation

    2 Jun 2025, 6:56PM Mankind Pharma Limited has informed the Exchange about Incorporation
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    27 May 2025, 3:17PM Mankind Pharma Limited has informed the Exchange about Transcript
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    27 May 2025, 9:50AM Mankind Pharma Limited has informed the Exchange about Schedule of meet
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    27 May 2025, 3:12PM Investor Conference Call for Q4 & FY25 - Transcript
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    27 May 2025, 9:44AM Intimation of participation in the Investor Conferences
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    22 May 2025, 1:03PM Intimation of participation in the Investor Conferences
  • Mankind Pharma - Copy of Newspaper Publication

    22 May 2025, 12:41PM Newspaper Publication of Audited Financial Results of Mankind Pharma Limited for the quarter and financial year ended on March 31, 2025
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    22 May 2025, 12:53PM Intimation of participation in the Investor Conferences
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    21 May 2025, 8:51PM Mankind Pharma Limited has informed the Exchange about Link of Recording
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    21 May 2025, 8:40PM Investor Conference Call for Q4 & FY25 - Audio Recording
  • Mankind Pharma - Acquisition-XBRL

    21 May 2025, 7:26PM Mankind Pharma Limited has informed the Exchange regarding Acquisition
  • Mankind Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    21 May 2025, 6:55PM MANKIND PHARMA LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agen
  • Mankind Pharma - Acquisition

    21 May 2025, 6:43PM Mankind Pharma Limited has informed the Exchange about Acquisition
  • Mankind Pharma - Change in Auditors

    21 May 2025, 6:32PM Mankind Pharma Limited has informed the Exchange regarding Change in Auditors of the company.
  • Mankind Pharma - Appointment Of Cost Auditor And Secretarial Auditor

    21 May 2025, 6:32PM Appointment of Cost Auditor and Secretarial Auditor
  • Mankind Pharma - General Updates

    21 May 2025, 6:29PM Outcome of Board Meeting
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Acquisition

    21 May 2025, 6:25PM Incorporation of WOS directly or indirectly in Sri Lanka
  • Mankind Pharma - Outcome Of Board Meeting

    21 May 2025, 6:19PM Outcome of Board Meeting
  • Mankind Pharma Q4 net profit down 15.79% at Rs 382.46 cr

    21 May 2025, 6:12PM The company reported standalone net profit of Rs 382.46 crore for the quarter ended March 31, 2025 as compared to Rs 454.17 crore in the same period l
  • Mankind Pharma - Investor Presentation

    21 May 2025, 6:08PM Mankind Pharma Limited has informed the Exchange about Investor Presentation
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    21 May 2025, 6:08PM Investor Presentation of Q4FY25
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    21 May 2025, 6:07PM Press Release - Q4FY25
  • Mankind Pharma - Outcome Of Board Meeting

    21 May 2025, 6:05PM Outcome of Board Meeting
  • Mankind Pharma - Press Release

    21 May 2025, 6:00PM Mankind Pharma Limited has informed the Exchange regarding a press release dated May 21, 2025, titled ""Press Release Q4FY25"".
  • Mankind Pharma - Outcome of Board Meeting

    21 May 2025, 5:58PM Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
  • Mankind Pharma - Alteration Of Capital and Fund Raising-XBRL

    21 May 2025, 11:01AM MANKIND PHARMA LIMITED has informed the Exchange regarding Allotment of Securities
  • Mankind Pharma - Allotment of Securities

    21 May 2025, 10:49AM Allotment of 92,512 Equity Shares under Mankind Employee Stock Option Plan2022
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    21 May 2025, 10:46AM Allotment of 92,512 Equity shares under Mankind Employee Stock Option Plan 2022
  • Mankind Pharma - General Updates

    15 May 2025, 5:54PM Mankind Pharma Limited has informed the Exchange about General Updates
  • Mankind Pharma - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclo

    15 May 2025, 5:51PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Mankind Pharma - Monitoring Agency Report

    14 May 2025, 8:07PM Monitoring Agency Report for the quarter ended on March 31, 2025
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    14 May 2025, 8:05PM Monitoring Agency Report for the quarter ended on March 31, 2025
  • Mankind Pharma - General Updates

    14 May 2025, 8:02PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Mankind Pharma - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclo

    14 May 2025, 8:00PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Mankind Pharma - General Updates

    14 May 2025, 7:55PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Mankind Pharma - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclo

    14 May 2025, 7:53PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    12 May 2025, 11:25AM Intimation of Investor Conference Call for Q4 & FY25 with Senior Management of Mankind Pharma Limited ( the Company )
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    12 May 2025, 11:19AM Intimation of Investor Conference Call for Q4 & FY25 with Senior Management of Mankind Pharma Limited ('the Company')\r\n\r\n
  • Mankind Pharma - General Updates

    11 May 2025, 9:50PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ( th
  • Mankind Pharma - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclo

    11 May 2025, 9:47PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements), Regulations, 2015
  • Mankind Pharma - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclo

    9 May 2025, 6:46PM Initmation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Mankind Pharma - General Updates

    9 May 2025, 6:42PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Mankind Pharma - Trading Window-XBRL

    8 May 2025, 7:14PM MANKIND PHARMA LIMITED has informed the Exchange about Closure of Trading Window
  • Mankind Pharma - Board Meeting Intimation

    8 May 2025, 6:52PM MANKIND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 21-May-2025 to inter-alia consider and approve the Audited Financia
  • Mankind Pharma - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 50 Of The SEBI (Listing Obl

    8 May 2025, 6:25PM Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2025 ,inter alia, to consider and a
  • Mankind Pharma - Disclosure under SEBI Takeover Regulations

    5 May 2025, 4:19PM Mankind Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substa
  • Mankind Pharma - Update-Acquisition/Scheme/Sale/Disposal-XBRL

    2 May 2025, 10:22PM MANKIND PHARMA LIMITED has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
  • Mankind Pharma - General Updates

    2 May 2025, 10:07PM Release of Pledge on the shares of Bharat Serums and Vaccines Limited, wholly owned subsidiary of the Company
  • Mankind Pharma - Release Of Pledge On The Shares Of Bharat Serums And Vaccines Limited, A Wholly Owned Subsidiary Of The Comp

    2 May 2025, 10:02PM Release of Pledge on the shares of Bharat Serums and Vaccines Limited, a wholly owned subsidiary of the Company
  • Mankind Pharma - Disclosure under SEBI Takeover Regulations

    30 Apr 2025, 12:20PM Ramesh Juneja For and on behalf of Promoters and Promoter Group of the Company has Submitted to the Exchange a copy of Disclosure under Regulation 31(
  • Mankind Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    19 Apr 2025, 5:10PM As of March 2025, 72.70% is owned by Indian Promoters and 27.30% by Public. <p align=justify> Institutional holds 24.39% (Insurance Companies 2.23%) a
  • Mankind Pharma - Acquisition-XBRL

    15 Apr 2025, 1:29PM Mankind Pharma Limited has informed the Exchange regarding Acquisition
  • Mankind Pharma - Acquisition-XBRL

    15 Apr 2025, 1:25PM Mankind Pharma Limited has informed the Exchange regarding Acquisition
  • Mankind Pharma to form committee for evaluating BSV integration

    15 Apr 2025, 8:53AM Mankind Pharma announced on Monday that its board has approved the formation of a committee to explore potential structures for integrating Bharat Ser
  • Mankind Pharma - Acquisition

    14 Apr 2025, 7:12PM Mankind Pharma Limited has informed the Exchange about Acquisition
  • Mankind Pharma - General Updates

    14 Apr 2025, 4:39PM Mankind Pharma Limited has informed the Exchange about General Updates
  • Mankind Pharma - Outcome of Board Meeting

    14 Apr 2025, 4:36PM Mankind Pharma Limited has informed the Exchange regarding Board meeting held on April 14, 2025.
  • Mankind Pharma - Compliances-Half Yearly Report (SEBI Circular No. CIR/IMD/DF-1/67/2017)

    11 Apr 2025, 5:09PM Disclosure pursuant to Paragraph 9.1 (a) of the Chapter VIII of SEBI Master Circular No. SEBI/HO/DDHS/PoD1/P/CIR/2024/54 dated May 22, 2024.
  • Mankind Pharma

    18 Sep 2024 , 10:52AM Mankind Pharma : Company's board to consider raising funds via NCDs, commercial papers, other debt securities among others on September 20. (Stock not under coverage)
  • Mankind Pharma

    10 Jul 2024 , 10:34AM Hema CIPEF to sell 0.9% stake worth Rs 763crore. Deal is expected at Rs 2061/share which is at 2% discount to previous closing price. Hema CIPEF currently owns 2.22% stake.
  • Mankind Pharma

    14 May 2024 , 12:15PM The Company is looking to acquire Bharat Serum and vaccines from PE Company Advent which has 100% ownership of Bharat Serum & vaccines & now is looking to exit. Positive read through.

Key fundamentals

Evaluate the intrinsic value of Mankind Pharma Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 21894.39 9623.8091 7783.911 6756.6684 4829.2702
Liabilities 21894.39 9623.8091 7783.911 6756.6684 4829.2702
Equity 41.26 40.0588 40.0588 40.0588 40.0588
Gross Profit 2562.55 2325.1047 1697.3814 1799.6143 1378.2913
Net Profit 1945.48 1823.4096 1248.258 1335.1306 1084.3747
Cash From Operating Activities 2322.16 1982.9732 1798.9871 812.2873 1022.3277
NPM(%) 20.48 19.68 15.35 18.39 19.61
Revenue 9497.8 9264.8093 8127.1532 7257.0359 5529.5985
Expenses 6935.25 6939.7046 6429.7718 5457.4216 4151.3072
ROE(%) 18.41 17.25 11.81 12.63 10.26

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Mankind Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 935.00 -1.22 31.02 1392.16 301.39 0.53
Lotus Eye Hospital and Institute Ltd 77.00 7.14 220.00 5072.84 3.55 0.00
Vaishali Pharma Ltd 11.76 2.89 196.00 2614.74 3.13 0.00
Astec Lifesciences Ltd 940.40 -0.49 0.00 4783.25 -601.21 0.00

Company Info

Our Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of our Company to a public limited company and as approved by our Shareholders pursuant to a special resolution dated July 14, 2005 the name of our Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.Major events and milestones:2004 Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar'tablets amongst others2005 -Set up our first manufacturing facility at Paonta Sahib, Himachal Pradesh-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others2007 -Entered the consumer healthcare segment with the launch of `Manforce' brand-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised ? 720 million from Monet Limited2009 Set up our manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh2010 Launched `Preganews' brand in the consumer healthcare segment2012 Setup our first R&D centre at IMT Manesar, Haryana2014 -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)-Set up our manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh2015 -Incorporated our Subsidiary, Lifestar Pharma LLC in the US-Incorporated our Subsidiary, Mankind Pharma Pte. Limited in Singapore2017 Set up our manufacturing facility in Sikkim2018 Our manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time2019 Entered the female infertility segment with the launch of `Dydroboon' tablets2020 -Incorporated our Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets2021 -Incorporated our Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets2022 -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others-Entered into oncology segment with the launch of `Pacliall' injection amongst others-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories-Our Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited. 2023 -Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence. -Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API. -Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution. 2024 -Mankind Pharma Completes Landmark Acquisition of BSV. -Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab. -Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups. -Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain).

Our Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of our Company to a public limited company and as approved by our Shareholders pursuant to a special resolution dated July 14, 2005 the name of our Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.Major events and milestones:2004 Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar'tablets amongst others2005 -Set up our first manufacturing facility at Paonta Sahib, Himachal Pradesh-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others2007 -Entered the consumer healthcare segment with the launch of `Manforce' brand-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised ? 720 million from Monet Limited2009 Set up our manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh2010 Launched `Preganews' brand in the consumer healthcare segment2012 Setup our first R&D centre at IMT Manesar, Haryana2014 -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)-Set up our manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh2015 -Incorporated our Subsidiary, Lifestar Pharma LLC in the US-Incorporated our Subsidiary, Mankind Pharma Pte. Limited in Singapore2017 Set up our manufacturing facility in Sikkim2018 Our manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time2019 Entered the female infertility segment with the launch of `Dydroboon' tablets2020 -Incorporated our Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets2021 -Incorporated our Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets2022 -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others-Entered into oncology segment with the launch of `Pacliall' injection amongst others-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories-Our Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited. 2023 -Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence. -Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API. -Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution. 2024 -Mankind Pharma Completes Landmark Acquisition of BSV. -Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab. -Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups. -Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain).

Read More

Parent Organisation

Mankind Pharma Ltd.

Founded

03/07/1991

Managing Director

Mr.Rajeev Juneja

NSE Symbol

MANKINDEQ

FAQ

The current price of Mankind Pharma Ltd is ₹ 2428.70.

The 52-week high for Mankind Pharma Ltd is ₹ 2465.60 and the 52-week low is ₹ 2425.00.

The market capitalization of Mankind Pharma Ltd is currently ₹ 100239.43. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Mankind Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Mankind Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Mankind Pharma Ltd shares.

The CEO of Mankind Pharma Ltd is Mr.Rajeev Juneja, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT